Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study for the FLAIR Endovascular Stent Graft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between 18 to 90 years of age whose hemodialysis access was a synthetic AV access graft located in an arm.~* Angiographic evidence of one or more stenoses, 7 cm or less in length and greater than or equal to 50%, at the graft-vein anastomosis of a synthetic AV access graft. The entire lesion must have been located within 7 cm of the anastomosis such that approximately 1 cm of the IMPRA/Bard Device must have extended into non-diseased vein and approximately 1 cm, but no more than 2 cm, of the IMPRA/Bard Device will be extended into non-diseased AV graft.~* Clinical evidence of a hemodynamically significant stenosis.~* Percutaneous endovascular therapy for the identified lesion was the best treatment choice in the opinion of the investigator.~* Patients must have been able to understand and provide informed consent.~* Patients whose synthetic AV access grafts had been implanted greater than 30 days and had undergone 1 or more successful hemodialysis sessions.~* During primary balloon angioplasty, full expansion of an appropriately sized angioplasty balloon, in the operator's judgment, must have been achieved.~Exclusion Criteria:~* Concomitant disease (e.g., terminal cancer) or other medical condition that was likely to result in death of the patient within 6 months of the time of implantation.~* Stenoses that had a corresponding thrombosis treated within 7 days.~* The presence of a second lesion in the access circuit less than or equal to 3 cm from the edges of the primary lesion that was treated within 30 days or that was greater than or equal to 30%. Access circuit was defined as the area from the AV access graft arterial anastomosis to the superior vena cava-right atrial junction.~* The presence of a second lesion in the access circuit greater than 3 cm from the edges of the primary lesion that was greater than or equal to 30%. Second lesions that were greater than or equal to 30% must have been treated prior to patient inclusion to reduce the percent stenosis to less than 30%.~* Patients who were unwilling or unable to return for follow-up visits or patients with whom follow-up visits may have been unreliable.~* Patients who had a stent placed at the target lesion site.~* Patients with a blood coagulative disorder or sepsis.~* Patients in which the IMPRA/Bard Device would have been required to cross an angle (between the inflow vein and synthetic AV access graft) that was greater than 90 degrees.~* Patients in which the IMPRA/Bard Device would have been required to be deployed fully across the elbow joint, which is identified radiographically by a combination of the humeroulnar joint and the humeroradial joint.~* Patients with a contraindication to the use of contrast media.~* Patients whose AV access graft was infected.~* Patients who were currently or were scheduled to enroll in other investigations that conflicted with follow-up testing or confounds data in this trial.~* Procedural use of another investigational device.~* Patients who were pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- FLAIR (Type: EXPERIMENTAL): Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
- PTA Only (Type: ACTIVE_COMPARATOR): Percutaneous Transluminal Angioplasty
- FLAIR Roll-in Participants (Type: EXPERIMENTAL): Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).